Im­munomedics CEO Michael Pehl hits the ex­it on the heels of a CRL and ac­cu­sa­tions of a da­ta in­tegri­ty breach

Fol­low­ing a rough few weeks, the re­volv­ing door at the ex­ec­u­tive suite to Im­munomedics $IM­MU is turn­ing once more.

Af­ter the mar­ket closed on Mon­day the com­pa­ny put out word that CEO Michael Pehl has de­cid­ed to leave for per­son­al rea­sons. His abrupt ex­it af­ter 15 months on the job comes a lit­tle more than a month af­ter the FDA hand­ed the com­pa­ny a CRL for its ap­pli­ca­tion to mar­ket the an­ti­body drug con­ju­gate IM­MU-132, or sac­i­tuzum­ab govite­can.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER